story of the week
Efficacy of the Anti-C5a Antibody Vilobelimab in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2022 Sep 07;[EPub Ahead of Print], APJ Vlaar, M Witzenrath, P van Paassen, LMA Heunks, B Mourvillier, S de Bruin, EHT Lim, MC Brouwer, PR Tuinman, JFK Saraiva, G Marx, SM Lobo, R Boldo, JA Simon-Campos, AD Cornet, A Grebenyuk, JM Engelbrecht, M Mukansi, PG Jorens, R Zerbib, S Rückinger, K Pilz, R Guo, D van de Beek, NC RiedemannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.